MA54283A - Pyrazoles utilisés utilisés comme modulateurs de l'hémoglobine - Google Patents

Pyrazoles utilisés utilisés comme modulateurs de l'hémoglobine

Info

Publication number
MA54283A
MA54283A MA054283A MA54283A MA54283A MA 54283 A MA54283 A MA 54283A MA 054283 A MA054283 A MA 054283A MA 54283 A MA54283 A MA 54283A MA 54283 A MA54283 A MA 54283A
Authority
MA
Morocco
Prior art keywords
pyrazoles
hemoglobin modulators
hemoglobin
modulators
pyrazoles used
Prior art date
Application number
MA054283A
Other languages
English (en)
Inventor
Shawn Cabral
Agustin Casimiro-Garcia
Ming Zhu Chen
Chulho Choi
Robert Lee Dow
Olugbeminiyi Omezia Fadeyi
Ariamala Gopalsamy
David Hepworth
Jayasankar Jasti
Lyn Howard Jones
Arjun Venkat Narayanan
Mihir Dineshkumar Parikh
David Walter Piotrowski
Lee Richard Roberts
Jr Ralph Pelton Robinson
Hatice Gizem Yayla
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA54283A publication Critical patent/MA54283A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054283A 2018-11-29 2019-11-26 Pyrazoles utilisés utilisés comme modulateurs de l'hémoglobine MA54283A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862772815P 2018-11-29 2018-11-29
US201962915784P 2019-10-16 2019-10-16

Publications (1)

Publication Number Publication Date
MA54283A true MA54283A (fr) 2022-03-09

Family

ID=68807213

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054283A MA54283A (fr) 2018-11-29 2019-11-26 Pyrazoles utilisés utilisés comme modulateurs de l'hémoglobine

Country Status (23)

Country Link
US (3) US11014908B2 (fr)
EP (1) EP3886984A1 (fr)
JP (1) JP2022510628A (fr)
KR (1) KR20210097161A (fr)
CN (1) CN113329789A (fr)
AU (1) AU2019387290A1 (fr)
BR (1) BR112021009057A2 (fr)
CA (1) CA3121139A1 (fr)
CO (1) CO2021006924A2 (fr)
CR (1) CR20210284A (fr)
CU (1) CU20210044A7 (fr)
DO (1) DOP2021000103A (fr)
EC (1) ECSP21037191A (fr)
IL (1) IL283408A (fr)
MA (1) MA54283A (fr)
MX (1) MX2021006095A (fr)
PE (1) PE20211592A1 (fr)
PH (1) PH12021551035A1 (fr)
PY (1) PY19100637A (fr)
SG (1) SG11202104585YA (fr)
TW (2) TWI736037B (fr)
UY (1) UY38488A (fr)
WO (1) WO2020109994A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11014908B2 (en) 2018-11-29 2021-05-25 Pfizer Inc. Chemical compounds
EP4093508A1 (fr) 2020-01-24 2022-11-30 Pfizer Inc. Anticorps anti-e-sélectine, compositions et procédés d'utilisation
CN112079774A (zh) * 2020-10-17 2020-12-15 甘肃天后光学科技有限公司 软性隐形眼镜用蓝光吸收剂、其制备方法及应用方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
TW200606133A (en) 2004-06-30 2006-02-16 Sankyo Co Substituted benzene compounds
JP2007176799A (ja) 2005-12-27 2007-07-12 Sankyo Co Ltd 置換ベンゼン化合物を含有する医薬
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
WO2011015524A2 (fr) 2009-08-03 2011-02-10 Bayer Cropscience Ag Dérivés d’hétérocycles fongicides
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
US8916593B2 (en) * 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
WO2012037204A1 (fr) 2010-09-14 2012-03-22 Exelixis, Inc. Inhibiteurs de pi3k-δ et leurs procédés d'utilisation et fabrication
WO2012129562A2 (fr) 2011-03-24 2012-09-27 The Scripps Research Institute Composés et procédés pour l'induction de la chondrogenèse
DK3738434T3 (da) 2011-12-28 2023-12-04 Global Blood Therapeutics Inc Mellemprodukter til opnåelse af substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsoxygenering
WO2013102145A1 (fr) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Composés d'aldéhydes hétéroaryles substitués et leurs procédés d'utilisation dans l'accroissement de l'oxygénation tissulaire
JP5791532B2 (ja) 2012-01-31 2015-10-07 株式会社ソシオネクスト 収容体及びリール
US20140271591A1 (en) * 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237330A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237361A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR102280614B1 (ko) 2013-03-15 2021-07-21 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
BR112015021982B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
US9248199B2 (en) * 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
JP2017518339A (ja) 2014-06-20 2017-07-06 インスティチュート パスツール コリア 抗感染化合物
WO2016043849A2 (fr) 2014-07-24 2016-03-24 Global Blood Therapeutics, Inc. Composés pour traiter le syndrome de détresse respiratoire aigu ou son effet négatif
WO2016071211A1 (fr) 2014-11-03 2016-05-12 F. Hoffmann-La Roche Ag Inhibiteurs de bace1
JP6914834B2 (ja) 2014-11-16 2021-08-04 アレイ バイオファーマ インコーポレイテッド （Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミド硫酸水素塩の結晶形
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US10787430B2 (en) 2016-06-17 2020-09-29 Fronthera U.S. Pharmaceuticals Llc Hemoglobin modifier compounds and uses thereof
EP3496717A4 (fr) 2016-08-15 2020-01-15 Purdue Research Foundation Dérivés d'aminoisoquinoléine substitués en position 4
US11014908B2 (en) * 2018-11-29 2021-05-25 Pfizer Inc. Chemical compounds

Also Published As

Publication number Publication date
UY38488A (es) 2020-06-30
JP2022510628A (ja) 2022-01-27
WO2020109994A1 (fr) 2020-06-04
CA3121139A1 (fr) 2020-06-04
US12103921B2 (en) 2024-10-01
US20220348555A1 (en) 2022-11-03
US20200172512A1 (en) 2020-06-04
US11014908B2 (en) 2021-05-25
AU2019387290A1 (en) 2021-05-27
US20230382892A1 (en) 2023-11-30
EP3886984A1 (fr) 2021-10-06
CN113329789A (zh) 2021-08-31
PH12021551035A1 (en) 2021-12-06
BR112021009057A2 (pt) 2021-08-10
TW202140452A (zh) 2021-11-01
PY19100637A (es) 2021-06-16
CR20210284A (es) 2021-07-09
PE20211592A1 (es) 2021-08-18
MX2021006095A (es) 2021-07-06
IL283408A (en) 2021-07-29
SG11202104585YA (en) 2021-06-29
CU20210044A7 (es) 2022-01-13
TW202033513A (zh) 2020-09-16
TWI736037B (zh) 2021-08-11
CO2021006924A2 (es) 2021-06-10
KR20210097161A (ko) 2021-08-06
DOP2021000103A (es) 2021-07-30
ECSP21037191A (es) 2021-06-30
US11702405B2 (en) 2023-07-18

Similar Documents

Publication Publication Date Title
EP3768854A4 (fr) Modulation de l'expression de hsd17b13
EP3935763A4 (fr) Plateforme de communication photonique
MA44008A (fr) 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b
EP3853365A4 (fr) Modulateurs de l'expression de pnpla3
EP3645100A4 (fr) Compensation d'insertion d'instrument
MX2020009947A (es) Amidas heterocíclicas útiles como moduladores de proteínas.
SI3880654T1 (sl) 2-formil-3-hidroksifeniloksimetilne spojine, zmožne modulirati hemoglobin
EP3820172A4 (fr) Solution de communication pour l'internet des véhicules
EP3954056A4 (fr) Amélioration d'efficacité de communication
EP3565410A4 (fr) Utilisation de picolinamides comme fongicides
MA53924A (fr) Modulateurs de l'expression d'apol1
EP4000451C0 (fr) Masque cosmétique pour les yeux
EP3601569A4 (fr) Modulateurs de l'expression de pcsk9
EP3530828A4 (fr) Raccord d'articulation
MA51645A (fr) Modulateurs de l'expression de dnm2
IL268905B (en) Phage therapy
EP4066436A4 (fr) Paramètres d'établissement de communication d'application
EP3704757A4 (fr) Composition d'électrolyte
EP3443969A4 (fr) Composition d'amélioration de la fonction cérébrale pour nouveau-nés
EP3518995C0 (fr) Composition d'alpha-tcp, de silicate et d'acide aminé phosphorylé
CL2019002723S1 (es) Segmento de acoplamiento.
MA51795A (fr) Oligonucléotides pour moduler l'expression de tmem106b
EP4020945A4 (fr) Terminal d'affichage
IL283408A (en) Pyrazoles as modulators of hemoglobin
FR3062793B1 (fr) Utilisation de 2,5-dicetopiperazines en tant qu'agents cosmetiques